KeyCorp (NYSE:KEY) reported quarterly earnings of $0.38 per share which missed the analyst consensus estimate of $0.54 by 29.63 percent. This is a 40.63 percent decrease over earnings of $0.64 per share from the same period last year.
Mustang Bio Announces First Patient Successfully Treated By Ex Vivo Lentiviral Gene Therapy To Treat RAG1 Severe Combined Immunodeficiency
Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for
